Epperla, N, Maddocks, KJ, Salhab, M, Chavez, JC, Reddy, N, Karmali, R, Umyarova, E, Bachanova, V, Costa, C, Glenn, M, Calzada, O, Xavier, AC, Zhou, Z, Hossain, NM, Hernandez-Ilizaliturri, FJ, Al-Mansour, Z, Barta, SK, Chhabra, S, Lansigan, F, Mehta, A, Jaglal, MV, Evans, A, Flowers, CR, Cohen, JB, Fenske, TS, Hamadani, M, and Costa, LJ. "C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy." Cancer 123, no. 22 (November 15, 2017): 4411-4418.
Epperla, N, Maddocks, KJ, Salhab, M, Chavez, JC, Reddy, N, Karmali, R, Umyarova, E, Bachanova, V, Costa, C, Glenn, M, Calzada, O, Xavier, AC, Zhou, Z, Hossain, NM, Hernandez-Ilizaliturri, FJ, Al-Mansour, Z, Barta, SK, Chhabra, S, Lansigan, F, Mehta, A, Jaglal, MV, Evans, A, Flowers, CR, Cohen, JB, Fenske, TS, Hamadani, M, and Costa, LJ. "C-MYC-positive relapsed and refractory, diffuse large B-cell lymphoma: Impact of additional “hits” and outcomes with subsequent therapy." Cancer 123, no. 22 (November 15, 2017): 4411-4418.
Landsburg, DJ, Falkiewicz, MK, Maly, J, Blum, KA, Howlett, C, Feldman, T, Mato, AR, Hill, BT, Li, S, Medeiros, LJ, Torka, P, Hernandez-Ilizaliturri, F, Reddy, NM, Singavi, A, Fenske, TS, Chavez, JC, Kaplan, JB, Behdad, A, Petrich, AM, Bast, MA, Vose, JM, Olszewski, AJ, Costa, C, Lansigan, F, Gerson, JN, Barta, SK, Calzada, O, Cohen, JB, Lue, JK, Amengual, JE, Rivera, X, Persky, DO, Peace, DJ, Nathan, S, and Cassaday, RD. "Outcomes of Patients With Double-Hit Lymphoma Who Achieve First Complete Remission." Journal of Clinical Oncology 35, no. 20 (July 10, 2017): 2260-2267.
Costa, LJ, Maddocks, K, Epperla, N, Reddy, NM, Karmali, R, Umyarova, E, Bachanova, V, Costa, C, Glenn, MJ, Chavez, JC, Calzada, O, Lansigan, F, Nasheed, H, Barta, SK, Zhou, Z, Jaglal, M, Chhabra, S, Hernandez-Ilizaliturri, F, Xavier, AC, Mehta, A, Peker, D, Forero-Torres, A, Al-Mansour, Z, Evens, AM, Cohen, JB, Flowers, CR, Fenske, TS, and Hamadani, M. "Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies." American Journal of Hematology 92, no. 2 (February 2017): e24615-e24615.
Costa, LJ, Maddocks, K, Epperla, N, Reddy, NM, Karmali, R, Umyarova, E, Bachanova, V, Costa, C, Glenn, MJ, Chavez, JC, Calzada, O, Lansigan, F, Nasheed, H, Barta, SK, Zhou, Z, Jaglal, M, Chhabra, S, Hernandez-Ilizaliturri, F, Xavier, AC, Mehta, A, Peker, D, Forero-Torres, A, Al-Mansour, Z, Evens, AM, Cohen, JB, Flowers, CR, Fenske, TS, and Hamadani, M. "Diffuse large B-cell lymphoma with primary treatment failure: Ultra-high risk features and benchmarking for experimental therapies." American Journal of Hematology 92, no. 2 (February 2017): e24615-e24615.
Costa, CA, Zaki, BI, Yen, SP, Winer, ES, Ryan, H, Findley, D, Metzler, SR, Shaw, L, Tsui, A, MacKenzie, TA, Beaven, AW, and Lansigan, F. "Short Course of Bendamustine and Rituximab Followed By 90Y-Ibritumomab Tiuxetan in Patients with Chemotherapy-Naive Follicular Lymphoma (FOL-BRITe): Final Report of Response Rates and Progression Free Survival." 58th Annual Meeting and Exposition of the American-Society-of-Hematology (ASH). San Diego, CA. December 3, 2016 - December 6, 2016.: AMER SOC HEMATOLOGY, December 2, 2016.